Market Overview - U.S. stocks traded higher, with the Nasdaq Composite gaining over 1% on Friday, while the Dow rose 0.55% to 48,216.43, and the S&P 500 increased by 0.83% to 6,830.85 [1] - Information technology shares rose by 1.6%, while consumer staples stocks fell by 0.4% [1] Company Performance - Nike Inc. shares fell around 10% despite reporting second-quarter revenue of $12.43 billion, exceeding analyst estimates of $12.22 billion, and earnings of 53 cents per share, surpassing estimates of 38 cents per share. The decline in gross margins for the second consecutive quarter contributed to the stock's drop [2] Commodity Market - Oil prices increased by 0.9% to $56.66, gold rose by 0.4% to $4,381.60, silver surged 3.4% to $67.415, and copper gained 1.1% to $5.4955 [5] European Market - European shares were higher, with the eurozone's STOXX 600 gaining 0.37%, Spain's IBEX 35 Index rising 0.22%, London's FTSE 100 up by 0.61%, Germany's DAX 40 increasing by 0.37%, and France's CAC 40 gaining 0.01% [6] Asian Market - Asian markets closed higher, with Japan's Nikkei 225 gaining 1.03%, Hong Kong's Hang Seng up by 0.75%, China's Shanghai Composite rising 0.36%, and India's BSE Sensex increasing by 0.53% [7] Notable Stock Movements - Autozi Internet Technology shares surged 54% to $2.34 after announcing a $90 million initial equity investment [9] - Amicus Therapeutics shares rose 31% to $14.20 following the announcement of its acquisition by BioMarin for a total equity value of about $4.8 billion, with BioMarin shares up 19% to $61.88 [9] - Lamb Weston Holdings shares dropped 25% to $44.70 after second-quarter results, while BlackBerry shares fell 10% to $3.90 following third-quarter results [9] - Mangoceuticals Inc. shares declined 45% to $0.72 after announcing a $100 million Solana-focused digital asset treasury strategy [9]

Core Viewpoint - Mangoceuticals, Inc. has successfully closed a registered direct offering and a concurrent private placement, raising approximately $2.5 million to support its health and wellness product development and operations [1][3]. Group 1: Offering Details - The transactions involved the sale of 1,930,502 Common Units, each consisting of one share of Common Stock or one Pre-Funded Warrant and one PIPE Common Warrant to purchase one share of Common Stock at an exercise price of $1.4245 [2]. - The offering price per Common Unit was set at $1.295, while the Pre-Funded Unit was priced at $1.29499, accounting for a minimal exercise price of $0.00001 per Pre-Funded Warrant [2]. - The Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised [2]. Group 2: Use of Proceeds - The net proceeds from the offerings, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Legal and Regulatory Aspects - Aegis Capital Corp. served as the exclusive placement agent for the offerings, and the registered direct offering was conducted under an effective shelf registration statement previously filed with the SEC [4]. - The securities sold in the private placement were not registered under the Securities Act and were offered only to accredited investors [5]. Group 4: Company Overview - Mangoceuticals, Inc. focuses on developing a range of men's health and wellness products through a secure telemedicine platform, targeting areas such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management [7].

来源：市场资讯 吴说获悉，纳斯达克上市公司 Mangoceuticals（MGRX）宣布与 Cube Group 合作推出最高 1 亿美元、聚 焦 Solana 的数字资产国库（DAT）战略，并成立子公司 Mango DAT 负责执行。公司称该计划将以 Solana 生态为核心，通过质押与 DeFi 收益实现 非摊薄增长，目标收益率区间为 7%–20%，并同步推进 RWA 代币化、稳定币财务体系及 DAT 2.0 扩展路径。 （来源：吴说） ...

Core Insights - The company has announced a $100 million Solana-focused digital asset treasury strategy in partnership with Cube Group, aiming to leverage high-yield opportunities for sustainable growth [1][2][11] Group 1: Strategic Initiatives - The initiative positions the company at the forefront of institutional adoption within the Solana ecosystem, focusing on optimized entry points for long-term value creation [2][12] - The strategy is led by Cube Group, which has a proven track record in digital asset treasuries, and will manage custody, execution, and overall strategy for the company [3][4] - The company has filed a trademark application for "MULTI-DAT," indicating its strategic expansion into the digital asset sector, allowing for various financial activities including virtual currency transactions and investment portfolio oversight [5] Group 2: Digital Asset Treasury 2.0 Strategy - The strategy includes evaluating corporate treasury allocations into established digital assets to diversify holdings and enhance balance-sheet efficiency [8] - It explores participation in tokenized real-world assets to gain liquidity and transparency in a regulated environment [8] - The company plans to integrate regulated stablecoins for treasury management and cross-border activities, aiming to streamline operations and advance its core business [8] Group 3: Yield and Growth Model - The strategy aims for annualized SOL staking yields of 7-8%, with active management targeting yields of 8-20% [16] - The company emphasizes a non-dilutive growth model, utilizing Solana's staking mechanisms to enhance shareholder value without diluting existing shares [9][10] - The initiative is designed to generate superior risk-adjusted returns and contribute to the broader adoption of digital assets in mainstream finance [12]

DALLAS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of shares of Common Stock and pre-funded warrants in a registered direct offering. In a concurrent private placement, the ...

Telemedicine Services - The company focuses on men's wellness telemedicine services, particularly in erectile dysfunction, hair loss, testosterone therapies, and weight management[374]. - The company operates its telehealth services through the website www.MangoRX.com[374]. - The company anticipates that healthcare professionals will prescribe products based on individual patient needs and medical history[377][382][388]. Product Information - The Mango ED product includes Sildenafil (50mg or 100mg), Tadalafil (10mg or 20mg), Oxytocin (100 IU), and L-Arginine (50mg) but has not been FDA approved[376][378]. - The Mango GROW product contains Minoxidil (2.5mg), Finasteride (1mg), Vitamin D3 (2000 IU), and Biotin (1mg) and is also not FDA approved[380][382]. - The SLIM product includes Vitamin B6 (10mg) and Semaglutide in varying doses (0.5mg to 2.0mg) and is produced under an exemption from FDA approval[384][385]. - The MOJO product consists of DHEA (10mg), Pregnenolone (5mg), and Enclomiphene Citrate (25mg) and is not FDA approved[387][388]. - All compounded products are produced by Epiq Scripts, LLC, a related party pharmacy[375]. - The compounded products can be replicated by other companies since the formulas are publicly disclosed[378][383]. - The company markets 'PRIME' by MangoRx, an FDA-approved oral Testosterone Replacement Therapy (TRT) product, which has shown 96% efficacy by day 90 in Phase 3 clinical research[391]. Financial Agreements and Funding - The company entered into a Consulting Agreement with ArcStone, issuing 100,000 shares valued at $257,000 for financial advisory services[399]. - An Intellectual Property Purchase Agreement was signed with Smokeless Technology Corp., involving the acquisition of certain IP for 1,600,000 shares and a 10% royalty on gross sales of related products[400]. - The company entered into a Master Distribution Agreement with PrevenTech, granting exclusive rights to sell antiviral products, with a revenue share of 10% from net sales[409]. - The company borrowed $500,000 from Indigo Capital LP, with an interest rate of 18% per annum, and later amended the note to allow conversion into shares at $1.50 per share[411][413]. - A Terms of Service Agreement with Levo Healthcare Consulting was established for digital marketing services, involving 120,000 shares and a revenue share of 4% from generated revenue[415]. - The company has a perpetual agreement with PrevenTech, with rights becoming non-exclusive if $5 million in gross sales is not achieved within 18 months[409]. - The company has agreed to pay a royalty of 10% on gross worldwide sales of products associated with the Purchased IP, effective from April 23, 2026[401]. - The company may seek additional funding through equity or debt financings, which could result in significant dilution to existing shareholders[442]. - The company anticipates needing additional funding to support operations for the next 12 months and may seek to raise funds through debt or equity offerings[540]. Financial Performance - Revenues for the three months ended September 30, 2025, were $84,246, a decrease of 37% from $133,368 in the same period of 2024, primarily due to issues with the transition to a new telehealth platform[445]. - General and administrative expenses decreased to $306,001 for the three months ended September 30, 2025, from $523,855 in 2024, mainly due to reductions in insurance and software expenses[449]. - Stock-based compensation increased significantly to $6,587,293 for the three months ended September 30, 2025, compared to $567,619 in 2024, attributed to greater use of equity-based incentives and a higher stock price[451]. - The net loss for the three months ended September 30, 2025, was $7,618,776, an increase of 281% from a net loss of $1,999,694 in the same period of 2024, primarily due to stock-based compensation[454]. - For the nine months ended September 30, 2025, revenues were $361,661, down 29% from $510,626 in 2024, again due to the transition to the new telehealth platform[455]. - Total current liabilities as of September 30, 2025, were $804,275, including $526,964 in accounts payable and accrued liabilities[470]. - The company had a total accumulated deficit of $39.5 million as of September 30, 2025[471]. - Cash on hand increased to $481,281 as of September 30, 2025, from $58,653 at the end of 2024, primarily due to financing activities[468]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $4,772,494, mainly due to a net loss of $17,854,207[476]. Stock and Equity Transactions - The Company issued 709,677 shares of restricted common stock for $1.55 per share, totaling $1,100,000 from accredited investors in August 2025[435]. - The Follow On Offering closed on December 19, 2023, resulting in the sale of 266,667 shares for total gross proceeds of $1.2 million[504]. - The net proceeds from the Offering were approximately $1.0 million, allocated for marketing and operational expenses related to Mango ED and GROW products[505]. - The Company issued a common stock purchase warrant for 18,667 shares at an exercise price of $5.70, valid until December 14, 2029[507]. - The April 2024 SPA was amended to expand the total purchase amount to $2.5 million, including 2,500 shares of Series B Convertible Preferred Stock[510]. - The April 2024 Purchaser converted 355 shares of Series B Convertible Preferred Stock into 128,245 shares of common stock at a conversion price of $3.05 per share[513]. - The April 2024 Purchaser converted 390 shares of Series B Convertible Preferred Stock into 160,222 shares of common stock at conversion prices ranging from $2.36 to $3.12 per share[516]. - The Tiger Cub Note was amended to allow conversion into shares of common stock at a conversion price of $1.785 per share[502]. - The Company granted Tiger Cub warrants to purchase 50,000 shares of common stock as part of the amended agreement[491]. - During the quarter ended March 31, 2025, holders of Series B Convertible Preferred Stock converted 1,438 shares into 623,333 shares of common stock at a conversion price of $1.00 per share[517]. - For the quarter ended June 30, 2025, holders converted 850 shares into 1,001,733 shares at conversion prices between $1.50 and $2.25 per share[518]. - The conversion price for Series B Convertible Preferred Stock was reduced to a fixed price of $1.50 per share from $2.25, effective March 17, 2025[519]. - As of September 30, 2025, the Company sold 666,667 shares under the Equity Line of Credit (ELOC) for gross proceeds of $1,787,580[525]. - The Company entered into a $25 million Equity Purchase Agreement on April 5, 2024, allowing the purchase of common stock over a two-year period[521]. - On June 10, 2025, the Company sold 261,667 shares of common stock under the ELOC for a total of $366,830, net of fees[524]. - The Company sold 250 shares of Series B Preferred Stock for $250,000 and warrants to purchase 330,000 shares at an exercise price of $2.71 per share in December 2024[526]. - The Investor Warrants have an exercise price of $3.00 per share and a term through May 23, 2028[536]. - The Company sold 70,000 shares of restricted common stock for $105,000 at $1.50 per share on February 3, 2025[532]. Accounting and Compliance - The company has implemented all new accounting pronouncements that may impact its financial statements and does not anticipate any material impact from recently issued standards that are not yet effective[549]. - In November 2023, the FASB issued ASU No. 2023-07, which updates reportable segment disclosure requirements, effective for annual periods beginning after December 15, 2023[551]. - ASU No. 2023-09, issued in December 2023, requires disaggregated information about a reporting entity's effective tax rate reconciliation, effective for annual periods beginning after December 15, 2024[552]. - The company classifies currently issued warrants in conjunction with its ordinary shares in permanent equity, measured at fair value[547]. - Stock-based compensation is accounted for based on the fair value of the award at the reporting date, impacting the financial statements significantly[543]. - The company utilizes the Black-Scholes option pricing model to estimate the fair value of stock options, which is influenced by various complex variables[544]. - The company has elected to take advantage of the extended transition period under the JOBS Act for complying with new accounting standards until it is no longer classified as an emerging growth company[548]. - Critical accounting policies reflect significant estimates and assumptions used in the preparation of the condensed consolidated financial statements[543]. - The company believes its financial statements are fairly stated in accordance with GAAP, despite inherent uncertainties in estimates[543]. - Changes in assumptions regarding stock-based awards can materially affect the fair value and the recognized compensation expense[544].

Core Viewpoint - Mangoceuticals (MGRX.US) experienced significant stock volatility following the retraction of a partnership announcement with Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) [1] Group 1: Company Developments - On Thursday, Mangoceuticals claimed to have established a partnership with Eli Lilly and Novo Nordisk to provide GLP-1 weight loss medications through its MangoRx Direct and PeachesRx Direct programs [1] - The following day, both Eli Lilly and Novo Nordisk publicly denied any existing partnership with Mangoceuticals, leading to a sharp decline in the company's stock price [1] Group 2: Stock Performance - Prior to the market opening, Mangoceuticals' stock fell approximately 13%, but later recovered slightly to close up 2.94% at $1.225 [1]

Core Viewpoint - Mangoceuticals (MGRX.US) experienced significant stock volatility following a retraction of its previous announcement regarding partnerships with Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) [1] Group 1: Stock Performance - The stock initially dropped approximately 13% in pre-market trading but later recovered to a slight increase of 2.94%, closing at $1.225 [1] Group 2: Partnership Announcement - On Thursday, Mangoceuticals claimed to have established partnerships with Eli Lilly and Novo Nordisk to provide GLP-1 weight loss medications through its MangoRx Direct and PeachesRx Direct programs [1] - This announcement was quickly contradicted as Eli Lilly publicly denied any partnership, and Novo Nordisk did not confirm the collaboration [1]

Group 1: RLX Technology Inc - RLX Technology Inc reported quarterly earnings of 3 cents per share on sales of $158.600 million [1] - Shares of RLX Technology rose 6% to $2.47 in pre-market trading following the earnings report [1] Group 2: Other Stocks in Pre-Market Trading - Cidara Therapeutics, Inc. surged 92% to $203.50 after a Schedule 13D Amendment revealed beneficial ownership of 3.37 million shares [4] - Binah Capital Group, Inc. gained 52.2% to $2.17 after posting stronger-than-expected third-quarter results [4] - Expion360 Inc. rose 42.4% to $1.81 following its third-quarter results [4] - Aspire Biopharma Holdings, Inc. surged 31.2% to $0.1380 in pre-market trading [4] - Invivyd, Inc. gained 28.8% to $2.28 after reporting better-than-expected third-quarter financial results [4] - Milestone Scientific Inc. surged 26.3% to $0.4801 after reporting better-than-expected third-quarter sales [4] - Lazydays Holdings, Inc. gained 23.3% to $1.85 after a previous surge [4] - Omeros Corp gained 12.5% to $7.08 following a narrower-than-expected quarterly loss [4] - Nouveau Monde Graphite Inc rose 10% to $3.25 after a decline the previous day [4] Group 3: Declining Stocks in Pre-Market Trading - TSS Inc tumbled 40.2% to $9.10 after reporting a year-over-year decrease in third-quarter results [4] - enVVeno Medical Corp declined 35.8% to $0.42 after an unfavorable FDA appeal decision [4] - Nuvve Holding Corp fell 29.3% to $0.34 after announcing third-quarter results [4] - ESS Tech Inc shares dipped 24.2% to $3.22 after reporting weak quarterly sales [4] - Direct Digital Holdings Inc fell 18.8% to $0.23 after a significant gain the previous day [4] - StubHub Holdings Inc fell 18.8% to $15.28 after worse-than-expected third-quarter EPS results [4] - Mangoceuticals Inc dipped 17.7% to $0.98 after a decline the previous day [4] - Red Cat Holdings Inc dipped 15.1% to $6.57 after worse-than-expected financial results and a lowered FY25 sales guidance [4] - WhiteFiber Inc fell 13.4% to $17.21 after reporting worse-than-expected financial results [4] - Sobr Safe Inc fell 12.4% to $2.21 after a decline the previous day [4]

Core Viewpoint - Mangoceuticals, Inc. has launched two weight-management programs, MangoRx Direct and PeachesRx Direct, allowing patients to access FDA-approved GLP-1 medications from Eli Lilly and Novo Nordisk through its platform [2][4]. Group 1: Program Details - The MangoRx Direct and PeachesRx Direct programs are licensed to issue valid prescriptions for GLP-1 medications, including Zepbound and Wegovy, through a third-party provider [2][5]. - Patients can fill prescriptions at any licensed pharmacy, with the medical operations and prescribing providers vetted by an independent third-party provider [3][5]. - The programs offer telehealth consultations, personalized care plans, and ongoing support for a monthly fee of $99, excluding medication costs [6]. Group 2: Company Overview - MangoRx focuses on men's health and wellness products via a secure telemedicine platform, targeting areas such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management [7]. - The company aims to provide a smooth telemedicine experience, with prescription requests reviewed by physicians and fulfilled through partner pharmacies [7].